ES2974902T3 - Moduladores de los canales Kv3 para tratar el dolor - Google Patents
Moduladores de los canales Kv3 para tratar el dolor Download PDFInfo
- Publication number
- ES2974902T3 ES2974902T3 ES16813020T ES16813020T ES2974902T3 ES 2974902 T3 ES2974902 T3 ES 2974902T3 ES 16813020 T ES16813020 T ES 16813020T ES 16813020 T ES16813020 T ES 16813020T ES 2974902 T3 ES2974902 T3 ES 2974902T3
- Authority
- ES
- Spain
- Prior art keywords
- oxy
- methyl
- alkyl
- pain
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 92
- 230000036407 pain Effects 0.000 title claims abstract description 71
- 150000001875 compounds Chemical class 0.000 claims abstract description 223
- 150000003839 salts Chemical class 0.000 claims abstract description 50
- 239000012453 solvate Substances 0.000 claims abstract description 40
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 238000011321 prophylaxis Methods 0.000 claims abstract description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 168
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims description 71
- 210000004027 cell Anatomy 0.000 claims description 65
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 63
- 229910052799 carbon Inorganic materials 0.000 claims description 62
- 208000004296 neuralgia Diseases 0.000 claims description 56
- 208000021722 neuropathic pain Diseases 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 41
- 125000005843 halogen group Chemical group 0.000 claims description 38
- 206010065390 Inflammatory pain Diseases 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 29
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 229910052731 fluorine Inorganic materials 0.000 claims description 27
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 27
- 241000282414 Homo sapiens Species 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 24
- 229910052801 chlorine Inorganic materials 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 21
- 230000001404 mediated effect Effects 0.000 claims description 20
- 208000000094 Chronic Pain Diseases 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 208000004454 Hyperalgesia Diseases 0.000 claims description 11
- 125000006413 ring segment Chemical group 0.000 claims description 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 7
- SKXPEZRPXUSJHY-IKJXHCRLSA-N (5r)-5-ethyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 SKXPEZRPXUSJHY-IKJXHCRLSA-N 0.000 claims description 6
- XYISZEPLGKRZAR-NYRJJRHWSA-N (5r)-5-ethyl-3-[6-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 XYISZEPLGKRZAR-NYRJJRHWSA-N 0.000 claims description 6
- BLJABDKRDIIYLJ-UHFFFAOYSA-N 3-[6-[(3-tert-butyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C2C(C(C)(C)C)OCC2=CC=C1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O BLJABDKRDIIYLJ-UHFFFAOYSA-N 0.000 claims description 6
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 6
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 208000035154 Hyperesthesia Diseases 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 238000002266 amputation Methods 0.000 claims description 4
- 230000009610 hypersensitivity Effects 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- MCSCOJJHSDROQX-QGZVFWFLSA-N (5r)-3-[2-[(2,2-difluoro-7-methyl-1,3-benzodioxol-4-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1OC(F)(F)O2 MCSCOJJHSDROQX-QGZVFWFLSA-N 0.000 claims description 3
- UTNPAJXEQYBRPF-JOCHJYFZSA-N (5r)-3-[4-[(3,3-dimethyl-1h-2-benzofuran-5-yl)oxy]phenyl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=C(COC2(C)C)C2=C1 UTNPAJXEQYBRPF-JOCHJYFZSA-N 0.000 claims description 3
- SHSPZEJVBTZRAQ-OAQYLSRUSA-N (5r)-3-[6-[(3,3-dimethyl-1h-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C)C2=C1 SHSPZEJVBTZRAQ-OAQYLSRUSA-N 0.000 claims description 3
- OWZHSHKAPQCKHB-MRXNPFEDSA-N (5r)-3-[6-[(3,3-dimethyl-1h-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C)C2=C1 OWZHSHKAPQCKHB-MRXNPFEDSA-N 0.000 claims description 3
- UTNAZRUUEYLOJF-CYBMUJFWSA-N (5r)-5-ethyl-3-[2-[(3,3,7-trimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C(C)(C)CO2 UTNAZRUUEYLOJF-CYBMUJFWSA-N 0.000 claims description 3
- AMAOXEGBJHLCSF-CQSZACIVSA-N (5r)-5-ethyl-3-[6-(3-methoxy-4-methylphenoxy)pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C(OC)=C1 AMAOXEGBJHLCSF-CQSZACIVSA-N 0.000 claims description 3
- YHKIKNMCENTLLI-CQSZACIVSA-N (5r)-5-ethyl-3-[6-[(3,3,7-trimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C(C)(C)CO2 YHKIKNMCENTLLI-CQSZACIVSA-N 0.000 claims description 3
- OYFGQTVERWVDGF-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-[2-[(3,3,7-trimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C(C)(C)CO2 OYFGQTVERWVDGF-OAQYLSRUSA-N 0.000 claims description 3
- 206010003011 Appendicitis Diseases 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000004983 Phantom Limb Diseases 0.000 claims description 3
- 206010056238 Phantom pain Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 229960002870 gabapentin Drugs 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 229960001233 pregabalin Drugs 0.000 claims description 3
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- GANVXLQPVDRZDP-QGZVFWFLSA-N (5r)-5-ethyl-3-(6-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC23CCC3)C2=C1 GANVXLQPVDRZDP-QGZVFWFLSA-N 0.000 claims description 2
- JFNGOQQEZATLIZ-CYBMUJFWSA-N (5r)-5-ethyl-3-[6-[4-methyl-3-(trifluoromethoxy)phenoxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C(OC(F)(F)F)=C1 JFNGOQQEZATLIZ-CYBMUJFWSA-N 0.000 claims description 2
- DZJBKKVCXVSFHQ-QGZVFWFLSA-N (5r)-5-ethyl-5-methyl-3-[2-[4-methyl-3-(trifluoromethoxy)phenoxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C(OC(F)(F)F)=C1 DZJBKKVCXVSFHQ-QGZVFWFLSA-N 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010053552 allodynia Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 208000009935 visceral pain Diseases 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002683 foot Anatomy 0.000 description 82
- 230000000694 effects Effects 0.000 description 78
- 108091006146 Channels Proteins 0.000 description 46
- 230000003447 ipsilateral effect Effects 0.000 description 41
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 29
- 230000035945 sensitivity Effects 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- 238000003556 assay Methods 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- 229940125904 compound 1 Drugs 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 229940125782 compound 2 Drugs 0.000 description 18
- 210000002569 neuron Anatomy 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 14
- 229940126214 compound 3 Drugs 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 238000007792 addition Methods 0.000 description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 229920000728 polyester Polymers 0.000 description 12
- -1 methoxy, propoxy Chemical group 0.000 description 11
- 230000003542 behavioural effect Effects 0.000 description 10
- 230000035601 cold sensitivity Effects 0.000 description 10
- JDXXXJZVGJSURS-UHFFFAOYSA-N 1-cyclohexyl-1-[(7,8-dimethyl-2-oxo-1h-quinolin-3-yl)methyl]-3-phenylurea Chemical compound O=C1NC2=C(C)C(C)=CC=C2C=C1CN(C(=O)NC=1C=CC=CC=1)C1CCCCC1 JDXXXJZVGJSURS-UHFFFAOYSA-N 0.000 description 9
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000002999 depolarising effect Effects 0.000 description 9
- 125000001153 fluoro group Chemical group F* 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 229960001848 lamotrigine Drugs 0.000 description 8
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 230000002981 neuropathic effect Effects 0.000 description 8
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 7
- 229960001259 diclofenac Drugs 0.000 description 7
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000003497 sciatic nerve Anatomy 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 6
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000036982 action potential Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 4
- NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000003923 Protein Kinase C Human genes 0.000 description 4
- 108090000315 Protein Kinase C Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 230000000763 evoking effect Effects 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- 229910001868 water Inorganic materials 0.000 description 4
- NPNNMBCPDXXEAG-CQSZACIVSA-N (5r)-5-ethyl-3-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 NPNNMBCPDXXEAG-CQSZACIVSA-N 0.000 description 3
- SXVVXFKHWPURFB-UHFFFAOYSA-N 3-methyl-4-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 SXVVXFKHWPURFB-UHFFFAOYSA-N 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 3
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 3
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 3
- 102000004257 Potassium Channel Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 125000001743 benzylic group Chemical group 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 3
- 229940097277 hygromycin b Drugs 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 108020001213 potassium channel Proteins 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960003312 retigabine Drugs 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- PXGUUSBQQRYVGW-FBLFFUNLSA-N (5r)-3-[2-[(3-cyclopropyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2C3CC3)C2=C1 PXGUUSBQQRYVGW-FBLFFUNLSA-N 0.000 description 2
- RFDFIGVUTNWOAX-IVAFLUGOSA-N (5r)-3-[2-[(3-tert-butyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2C(C)(C)C)C2=C1 RFDFIGVUTNWOAX-IVAFLUGOSA-N 0.000 description 2
- DLJGXIMVMXQVOL-AVKWCDSFSA-N (5r)-3-[6-[(3-cyclopropyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2C3CC3)C2=C1 DLJGXIMVMXQVOL-AVKWCDSFSA-N 0.000 description 2
- HEDYZGNKUJMEMM-LEQGEALCSA-N (5r)-3-[6-[(3-tert-butyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2C(C)(C)C)C2=C1 HEDYZGNKUJMEMM-LEQGEALCSA-N 0.000 description 2
- LSOZZXGDMKCFRV-MRXNPFEDSA-N (5r)-5-ethyl-3-(2-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyrimidin-5-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC23CCC3)C2=C1 LSOZZXGDMKCFRV-MRXNPFEDSA-N 0.000 description 2
- LWGBRPAONSBLOJ-CYBMUJFWSA-N (5r)-5-ethyl-3-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 LWGBRPAONSBLOJ-CYBMUJFWSA-N 0.000 description 2
- KUSCHUIKPGUDDF-OTOKDRCRSA-N (5r)-5-ethyl-3-[2-[(3-ethyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5-methylimidazolidine-2,4-dione Chemical compound C1=C2C(CC)OCC2=CC=C1OC(N=C1)=NC=C1N1C(=O)N[C@](C)(CC)C1=O KUSCHUIKPGUDDF-OTOKDRCRSA-N 0.000 description 2
- DJHFOZLDQVQSLW-GICMACPYSA-N (5r)-5-ethyl-3-[6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(CC)OC2 DJHFOZLDQVQSLW-GICMACPYSA-N 0.000 description 2
- VHCQGDDHMGSPCJ-FBLFFUNLSA-N (5r)-5-ethyl-3-[6-[(3-ethyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound C1=C2C(CC)OCC2=CC=C1OC(N=C1)=CC=C1N1C(=O)N[C@](C)(CC)C1=O VHCQGDDHMGSPCJ-FBLFFUNLSA-N 0.000 description 2
- SLCNIZVVOKLZCY-XPKAQORNSA-N (5r)-5-ethyl-5-methyl-3-[2-[[3-(trifluoromethyl)-1,3-dihydro-2-benzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2C(F)(F)F)C2=C1 SLCNIZVVOKLZCY-XPKAQORNSA-N 0.000 description 2
- OWUGDYTUCLRMTK-MRTLOADZSA-N (5r)-5-ethyl-5-methyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 OWUGDYTUCLRMTK-MRTLOADZSA-N 0.000 description 2
- DLKGQKBQEFLFBQ-OTOKDRCRSA-N (5r)-5-ethyl-5-methyl-3-[5-methyl-6-[[3-(trifluoromethyl)-1,3-dihydro-2-benzofuran-5-yl]oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=C1C)=CN=C1OC1=CC=C(COC2C(F)(F)F)C2=C1 DLKGQKBQEFLFBQ-OTOKDRCRSA-N 0.000 description 2
- RGQNUZIWDODFPM-VQCQRNETSA-N (5r)-5-ethyl-5-methyl-3-[5-methyl-6-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=C1C)=CN=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 RGQNUZIWDODFPM-VQCQRNETSA-N 0.000 description 2
- SNKUAWZFNNOCOP-LRTDYKAYSA-N (5r)-5-ethyl-5-methyl-3-[6-[[3-(trifluoromethyl)-1,3-dihydro-2-benzofuran-5-yl]oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2C(F)(F)F)C2=C1 SNKUAWZFNNOCOP-LRTDYKAYSA-N 0.000 description 2
- XHBQTBHBSLUMOU-FIWHBWSRSA-N (5r)-5-ethyl-5-methyl-3-[6-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 XHBQTBHBSLUMOU-FIWHBWSRSA-N 0.000 description 2
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 2
- PXHKOKCNQDWTHM-UHFFFAOYSA-N 3-[2-[(3-cyclopropyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2C3CC3)C2=C1 PXHKOKCNQDWTHM-UHFFFAOYSA-N 0.000 description 2
- YZAKZINCORTXJE-UHFFFAOYSA-N 3-[2-[(3-ethyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C2C(CC)OCC2=CC=C1OC(N=C1)=NC=C1N1C(=O)NC(C)(C)C1=O YZAKZINCORTXJE-UHFFFAOYSA-N 0.000 description 2
- DHHSJNRTOWLSOO-UHFFFAOYSA-N 3-[2-[(3-tert-butyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C2C(C(C)(C)C)OCC2=CC=C1OC(N=C1)=NC=C1N1C(=O)NC(C)(C)C1=O DHHSJNRTOWLSOO-UHFFFAOYSA-N 0.000 description 2
- CQVXHNZMCWCHQE-UHFFFAOYSA-N 3-[6-[(3-cyclopropyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2C3CC3)C2=C1 CQVXHNZMCWCHQE-UHFFFAOYSA-N 0.000 description 2
- UTGNGYYHQDVNBY-UHFFFAOYSA-N 3-[6-[(3-ethyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C2C(CC)OCC2=CC=C1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O UTGNGYYHQDVNBY-UHFFFAOYSA-N 0.000 description 2
- QJEJEPKGWPVGQU-UHFFFAOYSA-N 3-methyl-4-(6-spiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yloxypyridin-3-yl)-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1(CC1)CO2 QJEJEPKGWPVGQU-UHFFFAOYSA-N 0.000 description 2
- CZHVMIZYDXTWLF-UHFFFAOYSA-N 3-methyl-4-[6-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyridin-3-yl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 CZHVMIZYDXTWLF-UHFFFAOYSA-N 0.000 description 2
- IYAYIZYTDQZOAS-UHFFFAOYSA-N 4-[6-[(3-tert-butyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyridin-3-yl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2C(C)(C)C)C2=C1 IYAYIZYTDQZOAS-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010043087 Tachyphylaxis Diseases 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002102 hyperpolarization Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000001153 interneuron Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000008533 pain sensitivity Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000036278 prepulse Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000002336 repolarization Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- JESCETIFNOFKEU-SJORKVTESA-N (2s,5r)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide Chemical compound N1[C@H](C(=O)N)CC[C@@H]1C(C=C1)=CC=C1OCC1=CC=CC=C1F JESCETIFNOFKEU-SJORKVTESA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- XNTHGPIPYYQRHD-LJQANCHMSA-N (5r)-3-[2-(3-ethoxy-4-methylphenoxy)pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound C1=C(C)C(OCC)=CC(OC=2N=CC(=CN=2)N2C([C@@](C)(CC)NC2=O)=O)=C1 XNTHGPIPYYQRHD-LJQANCHMSA-N 0.000 description 1
- NOGMLHUFQIICMO-CQSZACIVSA-N (5r)-3-[2-(3-ethoxy-4-methylphenoxy)pyrimidin-5-yl]-5-ethylimidazolidine-2,4-dione Chemical compound C1=C(C)C(OCC)=CC(OC=2N=CC(=CN=2)N2C([C@@H](CC)NC2=O)=O)=C1 NOGMLHUFQIICMO-CQSZACIVSA-N 0.000 description 1
- LFBFJRDCNKBXII-MRXNPFEDSA-N (5r)-3-[2-[(2,2-difluoro-1,3-benzodioxol-4-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1OC(F)(F)O2 LFBFJRDCNKBXII-MRXNPFEDSA-N 0.000 description 1
- KWWAUFZMGKQKDI-OAQYLSRUSA-N (5r)-3-[2-[(3,3-diethyl-1h-2-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2(CC)CC)C2=C1 KWWAUFZMGKQKDI-OAQYLSRUSA-N 0.000 description 1
- NTIWPSOEUHNVTN-OAQYLSRUSA-N (5r)-3-[2-[(3,3-dimethyl-1,4-dihydroisochromen-5-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1CC(C)(C)OC2 NTIWPSOEUHNVTN-OAQYLSRUSA-N 0.000 description 1
- NGNJDTAVMXCKSV-HXUWFJFHSA-N (5r)-3-[2-[(3,3-dimethyl-1h-2-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2(C)C)C2=C1 NGNJDTAVMXCKSV-HXUWFJFHSA-N 0.000 description 1
- MUHADSVSTHSYGD-GFCCVEGCSA-N (5r)-3-[2-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]-5-ethylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C(C)(C)CO2 MUHADSVSTHSYGD-GFCCVEGCSA-N 0.000 description 1
- CLAKLXYCHLXXMD-MRXNPFEDSA-N (5r)-3-[2-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]-5-propan-2-ylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C(C)C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C(C)(C)CO2 CLAKLXYCHLXXMD-MRXNPFEDSA-N 0.000 description 1
- VGUVXVCVUZURSD-HXUWFJFHSA-N (5r)-3-[2-[(3,3-dimethyl-2h-1-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(OCC2(C)C)C2=C1 VGUVXVCVUZURSD-HXUWFJFHSA-N 0.000 description 1
- GFTJIMPCCPRHLU-OAQYLSRUSA-N (5r)-3-[2-[(4,4-dimethyl-1,3-dihydroisochromen-6-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COCC2(C)C)C2=C1 GFTJIMPCCPRHLU-OAQYLSRUSA-N 0.000 description 1
- DEZRPEPAVNAFNI-LLVKDONJSA-N (5r)-3-[4-(1,3-dihydro-2-benzofuran-4-yloxy)phenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=CC2=C1COC2 DEZRPEPAVNAFNI-LLVKDONJSA-N 0.000 description 1
- WNORIHLRCGIHAT-LLVKDONJSA-N (5r)-3-[4-(1,3-dihydro-2-benzofuran-5-yloxy)phenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=C(COC2)C2=C1 WNORIHLRCGIHAT-LLVKDONJSA-N 0.000 description 1
- HWOPDZORMNHOBO-SECBINFHSA-N (5r)-3-[4-(3-chloro-4-fluorophenoxy)phenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=C(F)C(Cl)=C1 HWOPDZORMNHOBO-SECBINFHSA-N 0.000 description 1
- PGVUDUKVQPXCFO-SECBINFHSA-N (5r)-3-[4-(3-chloro-5-fluorophenoxy)phenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC(F)=CC(Cl)=C1 PGVUDUKVQPXCFO-SECBINFHSA-N 0.000 description 1
- KUQFDHVMVBOROM-GFCCVEGCSA-N (5r)-3-[4-(3-methoxy-4-methylphenoxy)phenyl]-5-methylimidazolidine-2,4-dione Chemical compound C1=C(C)C(OC)=CC(OC=2C=CC(=CC=2)N2C([C@@H](C)NC2=O)=O)=C1 KUQFDHVMVBOROM-GFCCVEGCSA-N 0.000 description 1
- BTUINUKTQKREDG-GOSISDBHSA-N (5r)-3-[4-(3-methoxy-4-methylphenoxy)phenyl]-5-propan-2-ylimidazolidine-2,4-dione Chemical compound C1=C(C)C(OC)=CC(OC=2C=CC(=CC=2)N2C([C@@H](C(C)C)NC2=O)=O)=C1 BTUINUKTQKREDG-GOSISDBHSA-N 0.000 description 1
- YEJKKCUDPQULAD-LLVKDONJSA-N (5r)-3-[4-(3-methoxyphenoxy)phenyl]-5-methylimidazolidine-2,4-dione Chemical compound COC1=CC=CC(OC=2C=CC(=CC=2)N2C([C@@H](C)NC2=O)=O)=C1 YEJKKCUDPQULAD-LLVKDONJSA-N 0.000 description 1
- AIZFJFLYQMSWPM-GFCCVEGCSA-N (5r)-3-[4-(5-methoxy-2-methylphenoxy)phenyl]-5-methylimidazolidine-2,4-dione Chemical compound COC1=CC=C(C)C(OC=2C=CC(=CC=2)N2C([C@@H](C)NC2=O)=O)=C1 AIZFJFLYQMSWPM-GFCCVEGCSA-N 0.000 description 1
- JYJGIGZDJIZOOU-GFCCVEGCSA-N (5r)-3-[4-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]phenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=CC2=C1C(C)(C)CO2 JYJGIGZDJIZOOU-GFCCVEGCSA-N 0.000 description 1
- BHSLNPYKWBHNJV-GFCCVEGCSA-N (5r)-3-[4-[(3,6-dimethyl-1,2-benzoxazol-4-yl)oxy]phenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC(C)=CC2=C1C(C)=NO2 BHSLNPYKWBHNJV-GFCCVEGCSA-N 0.000 description 1
- JRJFHQWKQUKYGP-PUMZCOHWSA-N (5r)-3-[6-(1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7-yloxy)pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1CC1CO2 JRJFHQWKQUKYGP-PUMZCOHWSA-N 0.000 description 1
- KONDTIQYPDHQQI-GFCCVEGCSA-N (5r)-3-[6-(2,3-dimethylphenoxy)pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC(C)=C1C KONDTIQYPDHQQI-GFCCVEGCSA-N 0.000 description 1
- XLLHUAOUVJTIOP-GFCCVEGCSA-N (5r)-3-[6-(2,5-dimethylphenoxy)pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=N1)=CC=C1OC1=CC(C)=CC=C1C XLLHUAOUVJTIOP-GFCCVEGCSA-N 0.000 description 1
- UPBAATQVFMUENK-GFCCVEGCSA-N (5r)-3-[6-(2,6-dimethylphenoxy)pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=N1)=CC=C1OC1=C(C)C=CC=C1C UPBAATQVFMUENK-GFCCVEGCSA-N 0.000 description 1
- NCKSBRYDEQEYRF-LLVKDONJSA-N (5r)-3-[6-(2-ethylphenoxy)pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound CCC1=CC=CC=C1OC1=CC=C(N2C([C@@H](C)NC2=O)=O)C=N1 NCKSBRYDEQEYRF-LLVKDONJSA-N 0.000 description 1
- KYOIAWOEBRWZCH-LLVKDONJSA-N (5r)-3-[6-(3-methoxy-2-methylphenoxy)pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound COC1=CC=CC(OC=2N=CC(=CC=2)N2C([C@@H](C)NC2=O)=O)=C1C KYOIAWOEBRWZCH-LLVKDONJSA-N 0.000 description 1
- RAVHFGXUBIHMHW-LLVKDONJSA-N (5r)-3-[6-(3-methoxy-4-methylphenoxy)pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound C1=C(C)C(OC)=CC(OC=2N=CC(=CC=2)N2C([C@@H](C)NC2=O)=O)=C1 RAVHFGXUBIHMHW-LLVKDONJSA-N 0.000 description 1
- NMDUDTOVZPJHQQ-QGZVFWFLSA-N (5r)-3-[6-(3-methoxy-4-methylphenoxy)pyridin-3-yl]-5-propan-2-ylimidazolidine-2,4-dione Chemical compound C1=C(C)C(OC)=CC(OC=2N=CC(=CC=2)N2C([C@@H](C(C)C)NC2=O)=O)=C1 NMDUDTOVZPJHQQ-QGZVFWFLSA-N 0.000 description 1
- CEWFNICOTBKTGJ-LLVKDONJSA-N (5r)-3-[6-(5-methoxy-2-methylphenoxy)pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound COC1=CC=C(C)C(OC=2N=CC(=CC=2)N2C([C@@H](C)NC2=O)=O)=C1 CEWFNICOTBKTGJ-LLVKDONJSA-N 0.000 description 1
- CWQPAXHEMUDEFM-CQSZACIVSA-N (5r)-3-[6-[(2,2-dimethyl-3h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-5-ethylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1CC(C)(C)O2 CWQPAXHEMUDEFM-CQSZACIVSA-N 0.000 description 1
- NXFZEVSAUSOECI-JOCHJYFZSA-N (5r)-3-[6-[(3,3-diethyl-1h-2-benzofuran-4-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(CC)(CC)OC2 NXFZEVSAUSOECI-JOCHJYFZSA-N 0.000 description 1
- QOHXMTCRAKZKAS-JOCHJYFZSA-N (5r)-3-[6-[(3,3-diethyl-1h-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(CC)CC)C2=C1 QOHXMTCRAKZKAS-JOCHJYFZSA-N 0.000 description 1
- JXNSTUBOQNDSKJ-JOCHJYFZSA-N (5r)-3-[6-[(3,3-dimethyl-1,4-dihydroisochromen-5-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1CC(C)(C)OC2 JXNSTUBOQNDSKJ-JOCHJYFZSA-N 0.000 description 1
- QHYRGKMMPURNST-OAQYLSRUSA-N (5r)-3-[6-[(3,3-dimethyl-1h-2-benzofuran-4-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C)(C)OC2 QHYRGKMMPURNST-OAQYLSRUSA-N 0.000 description 1
- YLINUWFWUKIGBS-JOCHJYFZSA-N (5r)-3-[6-[(3,3-dimethyl-1h-2-benzofuran-5-yl)oxy]-5-methylpyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=C1C)=CN=C1OC1=CC=C(COC2(C)C)C2=C1 YLINUWFWUKIGBS-JOCHJYFZSA-N 0.000 description 1
- BANNWOFBMMRBFI-CYBMUJFWSA-N (5r)-3-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-5-ethylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C)(C)CO2 BANNWOFBMMRBFI-CYBMUJFWSA-N 0.000 description 1
- UFXXLHLRZQDWQK-LLVKDONJSA-N (5r)-3-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C)(C)CO2 UFXXLHLRZQDWQK-LLVKDONJSA-N 0.000 description 1
- AIKOGQLXSXLSOR-OAQYLSRUSA-N (5r)-3-[6-[(3,3-dimethyl-2h-1-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(OCC2(C)C)C2=C1 AIKOGQLXSXLSOR-OAQYLSRUSA-N 0.000 description 1
- KAAGFQARPRFVCV-OAHLLOKOSA-N (5r)-3-[6-[(3,3-dimethyl-2h-1-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(OCC2(C)C)C2=C1 KAAGFQARPRFVCV-OAHLLOKOSA-N 0.000 description 1
- ODYDLICXEYJNPP-JOCHJYFZSA-N (5r)-3-[6-[(4,4-dimethyl-1,3-dihydroisochromen-6-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COCC2(C)C)C2=C1 ODYDLICXEYJNPP-JOCHJYFZSA-N 0.000 description 1
- XOWFIAMSTPQWIU-CYBMUJFWSA-N (5r)-5-ethyl-3-(6-spiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1(CC1)CO2 XOWFIAMSTPQWIU-CYBMUJFWSA-N 0.000 description 1
- AKWYPYSMNSSAHJ-GOSISDBHSA-N (5r)-5-ethyl-3-[2-(3-methoxy-4-methylphenoxy)pyrimidin-5-yl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C(OC)=C1 AKWYPYSMNSSAHJ-GOSISDBHSA-N 0.000 description 1
- IRJYSDMKZFFBSU-MRXNPFEDSA-N (5r)-5-ethyl-3-[4-(3-methoxyphenoxy)phenyl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=C1)=CC=C1OC1=CC=CC(OC)=C1 IRJYSDMKZFFBSU-MRXNPFEDSA-N 0.000 description 1
- HAAFWNXQOYAZML-LJQANCHMSA-N (5r)-5-ethyl-3-[6-(3-methoxy-4-methylphenoxy)pyridin-3-yl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C(OC)=C1 HAAFWNXQOYAZML-LJQANCHMSA-N 0.000 description 1
- LEPKEFFNGWOANC-MRXNPFEDSA-N (5r)-5-ethyl-3-[6-(3-propan-2-ylphenoxy)pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC(C(C)C)=C1 LEPKEFFNGWOANC-MRXNPFEDSA-N 0.000 description 1
- UCUCGUSVXQPQHJ-CYBMUJFWSA-N (5r)-5-ethyl-3-[6-[(3-ethyl-1,2-benzoxazol-4-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(CC)=NO2 UCUCGUSVXQPQHJ-CYBMUJFWSA-N 0.000 description 1
- SUGOIOCOVYLITH-SBXXRYSUSA-N (5r)-5-ethyl-3-[6-[(3-methyl-1,3-dihydro-2-benzofuran-4-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C)OC2 SUGOIOCOVYLITH-SBXXRYSUSA-N 0.000 description 1
- KGOZBBRMSFXYCI-CYBMUJFWSA-N (5r)-5-ethyl-3-[6-[(3-propan-2-yl-1,2-benzoxazol-4-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C(C)C)=NO2 KGOZBBRMSFXYCI-CYBMUJFWSA-N 0.000 description 1
- MJACQPDTJQZOIH-HXUWFJFHSA-N (5r)-5-ethyl-5-methyl-3-(2-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyrimidin-5-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC23CCC3)C2=C1 MJACQPDTJQZOIH-HXUWFJFHSA-N 0.000 description 1
- NCCOXRAOCBVOBG-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-(2-spiro[1h-2-benzofuran-3,1'-cyclopentane]-5-yloxypyrimidin-5-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC23CCCC3)C2=C1 NCCOXRAOCBVOBG-OAQYLSRUSA-N 0.000 description 1
- DJFNGVMCJLQBNE-HXUWFJFHSA-N (5r)-5-ethyl-5-methyl-3-(2-spiro[2,3-dihydrochromene-4,1'-cyclopropane]-5-yloxypyrimidin-5-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C1(CC1)CCO2 DJFNGVMCJLQBNE-HXUWFJFHSA-N 0.000 description 1
- JBQMXBQRWQJAQB-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-(6-spiro[1,3-dihydroisochromene-4,1'-cyclopropane]-5-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1(CC1)COC2 JBQMXBQRWQJAQB-OAQYLSRUSA-N 0.000 description 1
- IHUKOBHPRYNGAA-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-(6-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC23CCC3)C2=C1 IHUKOBHPRYNGAA-OAQYLSRUSA-N 0.000 description 1
- NJSFHPVYLAMHCN-JOCHJYFZSA-N (5r)-5-ethyl-5-methyl-3-(6-spiro[1h-2-benzofuran-3,1'-cyclopentane]-5-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC23CCCC3)C2=C1 NJSFHPVYLAMHCN-JOCHJYFZSA-N 0.000 description 1
- CPDWLGQBLZMRST-HXUWFJFHSA-N (5r)-5-ethyl-5-methyl-3-(6-spiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1(CC1)CO2 CPDWLGQBLZMRST-HXUWFJFHSA-N 0.000 description 1
- LMDIRIJUNRBPAD-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-[2-[(2,4,4-trimethyl-3,1-benzoxazin-5-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C(C)(C)OC(C)=N2 LMDIRIJUNRBPAD-OAQYLSRUSA-N 0.000 description 1
- WGUQZTNFOFTICR-VLFLDKFOSA-N (5r)-5-ethyl-5-methyl-3-[2-[(4-methyl-3,4-dihydro-2h-chromen-5-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C(C)CCO2 WGUQZTNFOFTICR-VLFLDKFOSA-N 0.000 description 1
- ZRKOWATVZZCKMN-QUXALOBESA-N (5r)-5-ethyl-5-methyl-3-[6-[(3-methyl-3,4-dihydro-2h-chromen-5-yl)oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1CC(C)CO2 ZRKOWATVZZCKMN-QUXALOBESA-N 0.000 description 1
- JSJIKXPDVCODPV-LLVKDONJSA-N (5r)-5-methyl-3-[2-(3-propan-2-ylphenoxy)pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound CC(C)C1=CC=CC(OC=2N=CC(=CN=2)N2C([C@@H](C)NC2=O)=O)=C1 JSJIKXPDVCODPV-LLVKDONJSA-N 0.000 description 1
- RQZBWTHEVBEERL-GFCCVEGCSA-N (5r)-5-methyl-3-[4-(3-methylphenoxy)phenyl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=CC(C)=C1 RQZBWTHEVBEERL-GFCCVEGCSA-N 0.000 description 1
- WBZCSPNCZZLTMR-LLVKDONJSA-N (5r)-5-methyl-3-[4-[(3-methyl-1,2-benzoxazol-4-yl)oxy]phenyl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=CC2=C1C(C)=NO2 WBZCSPNCZZLTMR-LLVKDONJSA-N 0.000 description 1
- GFRIXFDKZVOXAV-GFCCVEGCSA-N (5r)-5-methyl-3-[6-(3-propan-2-yloxyphenoxy)pyridin-3-yl]imidazolidine-2,4-dione Chemical compound CC(C)OC1=CC=CC(OC=2N=CC(=CC=2)N2C([C@@H](C)NC2=O)=O)=C1 GFRIXFDKZVOXAV-GFCCVEGCSA-N 0.000 description 1
- LWIDVJYEQMQSQO-GFCCVEGCSA-N (5r)-5-methyl-3-[6-(3-propan-2-ylphenoxy)pyridin-3-yl]imidazolidine-2,4-dione Chemical compound CC(C)C1=CC=CC(OC=2N=CC(=CC=2)N2C([C@@H](C)NC2=O)=O)=C1 LWIDVJYEQMQSQO-GFCCVEGCSA-N 0.000 description 1
- NPLOCGGQYSBOPP-INIZCTEOSA-N (5r)-5-tert-butyl-3-[2-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](C(C)(C)C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1C(C)(C)CO2 NPLOCGGQYSBOPP-INIZCTEOSA-N 0.000 description 1
- LFVFRVPCLHKIJN-KRWDZBQOSA-N (5r)-5-tert-butyl-3-[6-(3-methoxy-4-methylphenoxy)pyridin-3-yl]imidazolidine-2,4-dione Chemical compound C1=C(C)C(OC)=CC(OC=2N=CC(=CC=2)N2C([C@H](NC2=O)C(C)(C)C)=O)=C1 LFVFRVPCLHKIJN-KRWDZBQOSA-N 0.000 description 1
- HWOPDZORMNHOBO-VIFPVBQESA-N (5s)-3-[4-(3-chloro-4-fluorophenoxy)phenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@H](C)NC(=O)N1C(C=C1)=CC=C1OC1=CC=C(F)C(Cl)=C1 HWOPDZORMNHOBO-VIFPVBQESA-N 0.000 description 1
- AMAOXEGBJHLCSF-AWEZNQCLSA-N (5s)-5-ethyl-3-[6-(3-methoxy-4-methylphenoxy)pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C(OC)=C1 AMAOXEGBJHLCSF-AWEZNQCLSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- MDTUWBLTRPRXBX-UHFFFAOYSA-N 1,2,4-triazol-3-one Chemical compound O=C1N=CN=N1 MDTUWBLTRPRXBX-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KGWNRZLPXLBMPS-UHFFFAOYSA-N 2h-1,3-oxazine Chemical compound C1OC=CC=N1 KGWNRZLPXLBMPS-UHFFFAOYSA-N 0.000 description 1
- LFHIGAAFNQHUPC-UHFFFAOYSA-N 3-[2-(2-tert-butylphenoxy)pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC(C)(C)C1=CC=CC=C1OC1=NC=C(N2C(C(C)(C)NC2=O)=O)C=N1 LFHIGAAFNQHUPC-UHFFFAOYSA-N 0.000 description 1
- HLDVEENPMLMRSM-UHFFFAOYSA-N 3-[2-[(3,3-diethyl-1h-2-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C2C(CC)(CC)OCC2=CC=C1OC(N=C1)=NC=C1N1C(=O)NC(C)(C)C1=O HLDVEENPMLMRSM-UHFFFAOYSA-N 0.000 description 1
- ZICPNWSAKOAKBG-UHFFFAOYSA-N 3-[2-[(3,3-dimethyl-1,4-dihydroisochromen-5-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=CC2=C1CC(C)(C)OC2 ZICPNWSAKOAKBG-UHFFFAOYSA-N 0.000 description 1
- GZJTXYMLKLJLEO-UHFFFAOYSA-N 3-[2-[(3,3-dimethyl-1h-2-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2(C)C)C2=C1 GZJTXYMLKLJLEO-UHFFFAOYSA-N 0.000 description 1
- RLZSNZIJMXBLGI-UHFFFAOYSA-N 3-[2-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C=12C(C)(C)COC2=CC=CC=1OC(N=C1)=NC=C1N1C(=O)NC(C)(C)C1=O RLZSNZIJMXBLGI-UHFFFAOYSA-N 0.000 description 1
- UTOYMVFQCHDTBV-UHFFFAOYSA-N 3-[2-[(3,3-dimethyl-2h-1-benzofuran-5-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C2C(C)(C)COC2=CC=C1OC(N=C1)=NC=C1N1C(=O)NC(C)(C)C1=O UTOYMVFQCHDTBV-UHFFFAOYSA-N 0.000 description 1
- DCQVJUJQVJIWPU-UHFFFAOYSA-N 3-[2-[(4,4-dimethyl-1,3-dihydroisochromen-6-yl)oxy]pyrimidin-5-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COCC2(C)C)C2=C1 DCQVJUJQVJIWPU-UHFFFAOYSA-N 0.000 description 1
- AUXBXMMBVFFUDC-UHFFFAOYSA-N 3-[4-(2,3-dimethylphenoxy)phenyl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1=CC=CC(OC=2C=CC(=CC=2)N2C(C(C)(C)NC2=O)=O)=C1C AUXBXMMBVFFUDC-UHFFFAOYSA-N 0.000 description 1
- ZJXSKCKSDWJWDC-UHFFFAOYSA-N 3-[6-(2,6-dimethylphenoxy)pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1=CC=CC(C)=C1OC1=CC=C(N2C(C(C)(C)NC2=O)=O)C=N1 ZJXSKCKSDWJWDC-UHFFFAOYSA-N 0.000 description 1
- VOSXOXREFBURNW-UHFFFAOYSA-N 3-[6-(2-ethylphenoxy)pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound CCC1=CC=CC=C1OC1=CC=C(N2C(C(C)(C)NC2=O)=O)C=N1 VOSXOXREFBURNW-UHFFFAOYSA-N 0.000 description 1
- KSMIANBVHCJDAE-UHFFFAOYSA-N 3-[6-(2-tert-butylphenoxy)pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC(C)(C)C1=CC=CC=C1OC1=CC=C(N2C(C(C)(C)NC2=O)=O)C=N1 KSMIANBVHCJDAE-UHFFFAOYSA-N 0.000 description 1
- HUZHREYEKKIFDK-UHFFFAOYSA-N 3-[6-(4-fluoro-2-methylphenoxy)pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1=CC(F)=CC=C1OC1=CC=C(N2C(C(C)(C)NC2=O)=O)C=N1 HUZHREYEKKIFDK-UHFFFAOYSA-N 0.000 description 1
- JRKBEQDYCHETRX-UHFFFAOYSA-N 3-[6-(4-fluoro-3-methylphenoxy)pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C(F)C(C)=CC(OC=2N=CC(=CC=2)N2C(C(C)(C)NC2=O)=O)=C1 JRKBEQDYCHETRX-UHFFFAOYSA-N 0.000 description 1
- HMLJINRNVYUTBC-UHFFFAOYSA-N 3-[6-[(3,3-diethyl-1h-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C2C(CC)(CC)OCC2=CC=C1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O HMLJINRNVYUTBC-UHFFFAOYSA-N 0.000 description 1
- QKKIXMMFPYSTEH-UHFFFAOYSA-N 3-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C=12C(C)(C)COC2=CC=CC=1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O QKKIXMMFPYSTEH-UHFFFAOYSA-N 0.000 description 1
- CPGJUZILFONYDJ-UHFFFAOYSA-N 3-[6-[(3,3-dimethyl-2h-1-benzofuran-5-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C2C(C)(C)COC2=CC=C1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O CPGJUZILFONYDJ-UHFFFAOYSA-N 0.000 description 1
- AOZHFMOQYJFMFL-UHFFFAOYSA-N 3-[6-[(3-ethyl-1,3-dihydro-2-benzofuran-4-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C=12C(CC)OCC2=CC=CC=1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O AOZHFMOQYJFMFL-UHFFFAOYSA-N 0.000 description 1
- BLQYVYOXUXLEPY-UHFFFAOYSA-N 3-[6-[(4,4-dimethyl-1,3-dihydroisochromen-6-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COCC2(C)C)C2=C1 BLQYVYOXUXLEPY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SWCKNZPFWDTENM-UHFFFAOYSA-N 3-methyl-4-(5-methyl-6-spiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yloxypyridin-3-yl)-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1C)=CN=C1OC1=CC=CC2=C1C1(CC1)CO2 SWCKNZPFWDTENM-UHFFFAOYSA-N 0.000 description 1
- MAYXIKTYUMBPIQ-UHFFFAOYSA-N 3-methyl-4-(6-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyridin-3-yl)-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC23CCC3)C2=C1 MAYXIKTYUMBPIQ-UHFFFAOYSA-N 0.000 description 1
- NQUBKMMQOUJYMZ-UHFFFAOYSA-N 3-methyl-4-(6-spiro[1h-2-benzofuran-3,1'-cyclopentane]-5-yloxypyridin-3-yl)-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC23CCCC3)C2=C1 NQUBKMMQOUJYMZ-UHFFFAOYSA-N 0.000 description 1
- BDINBEGKCACPFR-UHFFFAOYSA-N 3-methyl-4-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 BDINBEGKCACPFR-UHFFFAOYSA-N 0.000 description 1
- OKLXJCHECGELKY-UHFFFAOYSA-N 3-methyl-4-[4-(2-methylphenoxy)phenyl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=CC=CC=C1C OKLXJCHECGELKY-UHFFFAOYSA-N 0.000 description 1
- JPCZXWMSLWBUPH-UHFFFAOYSA-N 3-methyl-4-[4-(3-methylphenoxy)phenyl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=CC=CC(C)=C1 JPCZXWMSLWBUPH-UHFFFAOYSA-N 0.000 description 1
- CRDQQBJKVMJSBK-UHFFFAOYSA-N 3-methyl-4-[4-(3-propan-2-ylphenoxy)phenyl]-1h-1,2,4-triazol-5-one Chemical compound CC(C)C1=CC=CC(OC=2C=CC(=CC=2)N2C(NN=C2C)=O)=C1 CRDQQBJKVMJSBK-UHFFFAOYSA-N 0.000 description 1
- KURMQXDUSWKHDV-UHFFFAOYSA-N 3-methyl-4-[4-[3-(trifluoromethoxy)phenoxy]phenyl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=CC=CC(OC(F)(F)F)=C1 KURMQXDUSWKHDV-UHFFFAOYSA-N 0.000 description 1
- HAEHOTBKQOTAMS-UHFFFAOYSA-N 3-methyl-4-[4-[3-(trifluoromethyl)phenoxy]phenyl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=CC=CC(C(F)(F)F)=C1 HAEHOTBKQOTAMS-UHFFFAOYSA-N 0.000 description 1
- MLVZXLGUAWWQTM-UHFFFAOYSA-N 3-methyl-4-[5-methyl-6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1C)=CN=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 MLVZXLGUAWWQTM-UHFFFAOYSA-N 0.000 description 1
- AEWMLCWSDURMER-UHFFFAOYSA-N 3-methyl-4-[6-(3-propan-2-ylphenoxy)pyridin-3-yl]-1H-1,2,4-triazol-5-one Chemical compound CC(C)c1cccc(Oc2ccc(cn2)-n2c(C)n[nH]c2=O)c1 AEWMLCWSDURMER-UHFFFAOYSA-N 0.000 description 1
- QYACMTXZEJKARP-UHFFFAOYSA-N 3-methyl-4-[6-[(3,3,7-trimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C(C)(C)CO2 QYACMTXZEJKARP-UHFFFAOYSA-N 0.000 description 1
- KSWCRXAOXLLWTG-UHFFFAOYSA-N 3-methyl-4-[6-[4-methyl-3-(trifluoromethoxy)phenoxy]pyridin-3-yl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C(OC(F)(F)F)=C1 KSWCRXAOXLLWTG-UHFFFAOYSA-N 0.000 description 1
- NJRMOMWWHLVMPA-UHFFFAOYSA-N 4-[4-(2,3-dimethylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=CC=CC(C)=C1C NJRMOMWWHLVMPA-UHFFFAOYSA-N 0.000 description 1
- PWWRDVISZORIGY-UHFFFAOYSA-N 4-[4-(2,5-dimethylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=CC(C)=CC=C1C PWWRDVISZORIGY-UHFFFAOYSA-N 0.000 description 1
- PYBBOFCEIUGTFC-UHFFFAOYSA-N 4-[4-(2,6-dimethylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=C(C)C=CC=C1C PYBBOFCEIUGTFC-UHFFFAOYSA-N 0.000 description 1
- YGXKHVQVHCHPMB-UHFFFAOYSA-N 4-[4-(2-ethylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CCC1=CC=CC=C1OC1=CC=C(N2C(NN=C2C)=O)C=C1 YGXKHVQVHCHPMB-UHFFFAOYSA-N 0.000 description 1
- HNFWLUZIWLJEDP-UHFFFAOYSA-N 4-[4-(2-fluoro-6-methylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=C(C)C=CC=C1F HNFWLUZIWLJEDP-UHFFFAOYSA-N 0.000 description 1
- PBTGLAKUUZQCOX-UHFFFAOYSA-N 4-[4-(3,4-dimethylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=CC=C(C)C(C)=C1 PBTGLAKUUZQCOX-UHFFFAOYSA-N 0.000 description 1
- UTVLNIMGADRABB-UHFFFAOYSA-N 4-[4-(3,5-dimethylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=CC(C)=CC(C)=C1 UTVLNIMGADRABB-UHFFFAOYSA-N 0.000 description 1
- IFWWFBSJDUPWOE-UHFFFAOYSA-N 4-[4-(3-ethoxyphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CCOC1=CC=CC(OC=2C=CC(=CC=2)N2C(NN=C2C)=O)=C1 IFWWFBSJDUPWOE-UHFFFAOYSA-N 0.000 description 1
- MMYODIGMCPBBNL-UHFFFAOYSA-N 4-[4-(3-ethylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CCC1=CC=CC(OC=2C=CC(=CC=2)N2C(NN=C2C)=O)=C1 MMYODIGMCPBBNL-UHFFFAOYSA-N 0.000 description 1
- XSONJSCKMNUHGV-UHFFFAOYSA-N 4-[4-(3-methoxy-2-methylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound COC1=CC=CC(OC=2C=CC(=CC=2)N2C(NN=C2C)=O)=C1C XSONJSCKMNUHGV-UHFFFAOYSA-N 0.000 description 1
- FQCSOVIZRJNGQV-UHFFFAOYSA-N 4-[4-(3-methoxy-4-methylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound C1=C(C)C(OC)=CC(OC=2C=CC(=CC=2)N2C(NN=C2C)=O)=C1 FQCSOVIZRJNGQV-UHFFFAOYSA-N 0.000 description 1
- QRIPGYGUKLYSAX-UHFFFAOYSA-N 4-[4-(3-methoxyphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound COC1=CC=CC(OC=2C=CC(=CC=2)N2C(NN=C2C)=O)=C1 QRIPGYGUKLYSAX-UHFFFAOYSA-N 0.000 description 1
- NBGXVOXMPPZUHR-UHFFFAOYSA-N 4-[4-(3-methylphenoxy)phenyl]-1H-1,2,4-triazol-5-one Chemical compound Cc1cccc(Oc2ccc(cc2)-n2cn[nH]c2=O)c1 NBGXVOXMPPZUHR-UHFFFAOYSA-N 0.000 description 1
- GVUUMTPBEYAKJM-UHFFFAOYSA-N 4-[4-(4-fluoro-3-methoxyphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound C1=C(F)C(OC)=CC(OC=2C=CC(=CC=2)N2C(NN=C2C)=O)=C1 GVUUMTPBEYAKJM-UHFFFAOYSA-N 0.000 description 1
- OFEZEJXVRWEDRO-UHFFFAOYSA-N 4-[4-(5-methoxy-2-methylphenoxy)phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound COC1=CC=C(C)C(OC=2C=CC(=CC=2)N2C(NN=C2C)=O)=C1 OFEZEJXVRWEDRO-UHFFFAOYSA-N 0.000 description 1
- CXOVLXHTGLQPCU-UHFFFAOYSA-N 4-[4-[3-(dimethylamino)phenoxy]phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CN(C)C1=CC=CC(OC=2C=CC(=CC=2)N2C(NN=C2C)=O)=C1 CXOVLXHTGLQPCU-UHFFFAOYSA-N 0.000 description 1
- PNAKZBIOKBEYPQ-UHFFFAOYSA-N 4-[4-[4-fluoro-3-(trifluoromethoxy)phenoxy]phenyl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1)=CC=C1OC1=CC=C(F)C(OC(F)(F)F)=C1 PNAKZBIOKBEYPQ-UHFFFAOYSA-N 0.000 description 1
- ANICYERZZAFUOC-UHFFFAOYSA-N 4-[5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)pyridin-2-yl]oxy-2-(trifluoromethoxy)benzonitrile Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C#N)C(OC(F)(F)F)=C1 ANICYERZZAFUOC-UHFFFAOYSA-N 0.000 description 1
- SCNZQQOTOHGJCN-UHFFFAOYSA-N 4-[5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)pyridin-2-yl]oxy-2-ethoxybenzonitrile Chemical compound C1=C(C#N)C(OCC)=CC(OC=2N=CC(=CC=2)N2C(C(C)(C)NC2=O)=O)=C1 SCNZQQOTOHGJCN-UHFFFAOYSA-N 0.000 description 1
- DTQYJSBEDXCYPY-UHFFFAOYSA-N 4-[5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)pyridin-2-yl]oxy-2-ethylbenzonitrile Chemical compound C1=C(C#N)C(CC)=CC(OC=2N=CC(=CC=2)N2C(C(C)(C)NC2=O)=O)=C1 DTQYJSBEDXCYPY-UHFFFAOYSA-N 0.000 description 1
- AGHZEKIJFOMEIB-UHFFFAOYSA-N 4-[5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)pyridin-2-yl]oxy-2-methoxybenzonitrile Chemical compound C1=C(C#N)C(OC)=CC(OC=2N=CC(=CC=2)N2C(C(C)(C)NC2=O)=O)=C1 AGHZEKIJFOMEIB-UHFFFAOYSA-N 0.000 description 1
- NGZQBJVNNWBFSH-UHFFFAOYSA-N 4-[5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)pyridin-2-yl]oxy-2-propan-2-ylbenzonitrile Chemical compound C1=C(C#N)C(C(C)C)=CC(OC=2N=CC(=CC=2)N2C(C(C)(C)NC2=O)=O)=C1 NGZQBJVNNWBFSH-UHFFFAOYSA-N 0.000 description 1
- IGOVPXNEHNQYNI-UHFFFAOYSA-N 4-[5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)pyridin-2-yl]oxy-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC(OC=2N=CC(=CC=2)N2C(C(C)(C)NC2=O)=O)=C1 IGOVPXNEHNQYNI-UHFFFAOYSA-N 0.000 description 1
- UXAHHXXMSQCKRN-UHFFFAOYSA-N 4-[5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)pyridin-2-yl]oxy-3-(trifluoromethyl)benzonitrile Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C#N)C=C1C(F)(F)F UXAHHXXMSQCKRN-UHFFFAOYSA-N 0.000 description 1
- DDURMVVZNDJGQP-UHFFFAOYSA-N 4-[5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)pyridin-2-yl]oxy-3-ethylbenzonitrile Chemical compound CCC1=CC(C#N)=CC=C1OC1=CC=C(N2C(C(C)(C)NC2=O)=O)C=N1 DDURMVVZNDJGQP-UHFFFAOYSA-N 0.000 description 1
- RDOJVSRQASEHPG-UHFFFAOYSA-N 4-[5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)pyridin-2-yl]oxy-3-methylbenzonitrile Chemical compound CC1=CC(C#N)=CC=C1OC1=CC=C(N2C(C(C)(C)NC2=O)=O)C=N1 RDOJVSRQASEHPG-UHFFFAOYSA-N 0.000 description 1
- MYOYKPGYUWLSEY-UHFFFAOYSA-N 4-[5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)pyrimidin-2-yl]oxy-2-ethylbenzonitrile Chemical compound C1=C(C#N)C(CC)=CC(OC=2N=CC(=CN=2)N2C(C(C)(C)NC2=O)=O)=C1 MYOYKPGYUWLSEY-UHFFFAOYSA-N 0.000 description 1
- KAFDWVNRZRPCEJ-UHFFFAOYSA-N 4-[6-(2,3-dimethylphenoxy)pyridin-3-yl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=CC(C)=C1C KAFDWVNRZRPCEJ-UHFFFAOYSA-N 0.000 description 1
- NUTDLFJSTOHFNY-UHFFFAOYSA-N 4-[6-(3-ethoxyphenoxy)-5-methylpyridin-3-yl]-3-methyl-1H-1,2,4-triazol-5-one Chemical compound CCOc1cccc(Oc2ncc(cc2C)-n2c(C)n[nH]c2=O)c1 NUTDLFJSTOHFNY-UHFFFAOYSA-N 0.000 description 1
- JPYJRVVTGDSUAV-UHFFFAOYSA-N 4-[6-(3-propan-2-ylphenoxy)pyridin-3-yl]-1H-1,2,4-triazol-5-one Chemical compound CC(C)c1cccc(Oc2ccc(cn2)-n2cn[nH]c2=O)c1 JPYJRVVTGDSUAV-UHFFFAOYSA-N 0.000 description 1
- GADKJUHCHUWHKA-UHFFFAOYSA-N 4-[6-[(3,3-diethyl-1h-2-benzofuran-5-yl)oxy]pyridin-3-yl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound C1=C2C(CC)(CC)OCC2=CC=C1OC(N=C1)=CC=C1N1C(C)=NNC1=O GADKJUHCHUWHKA-UHFFFAOYSA-N 0.000 description 1
- IRMDVYGLPAWMSG-UHFFFAOYSA-N 4-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]-5-methylpyridin-3-yl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=C1C)=CN=C1OC1=CC=CC2=C1C(C)(C)CO2 IRMDVYGLPAWMSG-UHFFFAOYSA-N 0.000 description 1
- FWBDVGGUCXZCAY-UHFFFAOYSA-N 4-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C)(C)CO2 FWBDVGGUCXZCAY-UHFFFAOYSA-N 0.000 description 1
- RZHPRAFVXFPVPT-UHFFFAOYSA-N 4-[6-[(3-tert-butyl-1,3-dihydro-2-benzofuran-4-yl)oxy]pyridin-3-yl]-3-methyl-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C(C(C)(C)C)OC2 RZHPRAFVXFPVPT-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- PFWPHOLELOXFFV-UHFFFAOYSA-N 5,5-dimethyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 PFWPHOLELOXFFV-UHFFFAOYSA-N 0.000 description 1
- VXCFTYWNOQFXHH-UHFFFAOYSA-N 5,5-dimethyl-3-[6-[4-methyl-3-(trifluoromethoxy)phenoxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound C1=C(OC(F)(F)F)C(C)=CC=C1OC1=CC=C(N2C(C(C)(C)NC2=O)=O)C=N1 VXCFTYWNOQFXHH-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- FUTZCNTWTBPWAV-UHFFFAOYSA-N 6-[6-(3-methoxy-4-methylphenoxy)pyridin-3-yl]-4,6-diazaspiro[2.4]heptane-5,7-dione Chemical compound C1=C(C)C(OC)=CC(OC=2N=CC(=CC=2)N2C(C3(CC3)NC2=O)=O)=C1 FUTZCNTWTBPWAV-UHFFFAOYSA-N 0.000 description 1
- ZJEURBVUUVBUMC-UHFFFAOYSA-N 6-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-4,6-diazaspiro[2.4]heptane-5,7-dione Chemical compound C=12C(C)(C)COC2=CC=CC=1OC(N=C1)=CC=C1N(C1=O)C(=O)NC21CC2 ZJEURBVUUVBUMC-UHFFFAOYSA-N 0.000 description 1
- MCZVVEAVQUTBQO-UHFFFAOYSA-N 7-[6-(3-methoxy-4-methylphenoxy)pyridin-3-yl]-5,7-diazaspiro[3.4]octane-6,8-dione Chemical compound C1=C(C)C(OC)=CC(OC=2N=CC(=CC=2)N2C(C3(CCC3)NC2=O)=O)=C1 MCZVVEAVQUTBQO-UHFFFAOYSA-N 0.000 description 1
- GOPBAXGLRUCBSV-UHFFFAOYSA-N 7-[6-[(3,3-dimethyl-2h-1-benzofuran-4-yl)oxy]pyridin-3-yl]-5,7-diazaspiro[3.4]octane-6,8-dione Chemical compound C=12C(C)(C)COC2=CC=CC=1OC(N=C1)=CC=C1N(C1=O)C(=O)NC21CCC2 GOPBAXGLRUCBSV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000242762 Anemonia sulcata Species 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241001638933 Cochlicella barbara Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101001049859 Homo sapiens Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 description 1
- 101001049849 Homo sapiens Calcium-activated potassium channel subunit beta-1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 1
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108700032993 adenovirus CELO Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000058066 human KCNMA1 Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000017813 membrane repolarization Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008052 pain pathway Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000003894 surgical glue Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1521751.6A GB201521751D0 (en) | 2015-12-10 | 2015-12-10 | Novel uses |
| PCT/GB2016/053879 WO2017098254A1 (en) | 2015-12-10 | 2016-12-09 | Modulators of kv3 channels to treat pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2974902T3 true ES2974902T3 (es) | 2024-07-02 |
Family
ID=55274489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16813020T Active ES2974902T3 (es) | 2015-12-10 | 2016-12-09 | Moduladores de los canales Kv3 para tratar el dolor |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11147813B2 (enExample) |
| EP (1) | EP3386506B1 (enExample) |
| JP (3) | JP7149847B2 (enExample) |
| KR (1) | KR102812887B1 (enExample) |
| CN (2) | CN118267386A (enExample) |
| AU (1) | AU2016367239B2 (enExample) |
| BR (1) | BR112018011700B1 (enExample) |
| CA (1) | CA3005302A1 (enExample) |
| DK (1) | DK3386506T3 (enExample) |
| EA (1) | EA038059B1 (enExample) |
| ES (1) | ES2974902T3 (enExample) |
| FI (1) | FI3386506T3 (enExample) |
| GB (1) | GB201521751D0 (enExample) |
| HR (1) | HRP20240497T1 (enExample) |
| HU (1) | HUE066879T2 (enExample) |
| IL (1) | IL259717B (enExample) |
| MX (1) | MX385578B (enExample) |
| PL (1) | PL3386506T3 (enExample) |
| PT (1) | PT3386506T (enExample) |
| SG (1) | SG11201804123VA (enExample) |
| WO (1) | WO2017098254A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| US20200039970A1 (en) | 2016-12-16 | 2020-02-06 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| WO2018220762A1 (ja) * | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| US12358901B2 (en) * | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| FI3867247T3 (fi) * | 2018-10-16 | 2024-10-30 | Autifony Therapeutics Ltd | Uusia yhdisteitä |
| AR116898A1 (es) * | 2018-10-30 | 2021-06-23 | H Lundbeck As | DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3 |
| SG11202104374WA (en) | 2018-11-30 | 2021-05-28 | Otsuka Pharma Co Ltd | Heterocyclic compounds for the treatment of epilepsy |
| BR112022013339A2 (pt) | 2020-02-06 | 2022-09-13 | Autifony Therapeutics Ltd | Moduladores de kv3 |
| WO2023017263A1 (en) | 2021-08-10 | 2023-02-16 | Autifony Therapeutics Limited | Potassium channel modulators |
| CN113788741B (zh) * | 2021-09-28 | 2023-12-29 | 大连九信精细化工有限公司 | 一种制备2-环丙基苯酚衍生物的方法 |
| EP4630117A1 (en) | 2022-12-06 | 2025-10-15 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102083792A (zh) | 2008-06-06 | 2011-06-01 | Ucb医药有限公司 | 包含环丁氧基的化合物 |
| BR112012015868A2 (pt) * | 2009-12-11 | 2017-06-20 | Autifony Therapeutics Ltd | derivados de imidazolidinadiona |
| WO2012076877A1 (en) | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| EP2718285B1 (en) | 2011-06-07 | 2016-03-16 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| CA2856654C (en) * | 2011-12-06 | 2020-03-31 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| CN104334547B (zh) * | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| BR112014028718A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | derivados de hidantoína como inibidores de kv3 |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
-
2015
- 2015-12-10 GB GBGB1521751.6A patent/GB201521751D0/en not_active Ceased
-
2016
- 2016-12-09 ES ES16813020T patent/ES2974902T3/es active Active
- 2016-12-09 BR BR112018011700-5A patent/BR112018011700B1/pt active IP Right Grant
- 2016-12-09 HU HUE16813020A patent/HUE066879T2/hu unknown
- 2016-12-09 PL PL16813020.1T patent/PL3386506T3/pl unknown
- 2016-12-09 CA CA3005302A patent/CA3005302A1/en active Pending
- 2016-12-09 DK DK16813020.1T patent/DK3386506T3/da active
- 2016-12-09 PT PT168130201T patent/PT3386506T/pt unknown
- 2016-12-09 SG SG11201804123VA patent/SG11201804123VA/en unknown
- 2016-12-09 JP JP2018529633A patent/JP7149847B2/ja active Active
- 2016-12-09 CN CN202410102663.8A patent/CN118267386A/zh active Pending
- 2016-12-09 CN CN201680072639.8A patent/CN108472288B/zh active Active
- 2016-12-09 FI FIEP16813020.1T patent/FI3386506T3/fi active
- 2016-12-09 WO PCT/GB2016/053879 patent/WO2017098254A1/en not_active Ceased
- 2016-12-09 MX MX2018007074A patent/MX385578B/es unknown
- 2016-12-09 US US16/060,714 patent/US11147813B2/en active Active
- 2016-12-09 AU AU2016367239A patent/AU2016367239B2/en active Active
- 2016-12-09 EA EA201891377A patent/EA038059B1/ru unknown
- 2016-12-09 EP EP16813020.1A patent/EP3386506B1/en active Active
- 2016-12-09 KR KR1020187017088A patent/KR102812887B1/ko active Active
- 2016-12-09 HR HRP20240497TT patent/HRP20240497T1/hr unknown
-
2018
- 2018-05-30 IL IL259717A patent/IL259717B/en active IP Right Grant
-
2021
- 2021-09-10 US US17/472,493 patent/US11944623B2/en active Active
-
2022
- 2022-06-30 JP JP2022106247A patent/JP2022141699A/ja active Pending
-
2024
- 2024-01-30 US US18/427,639 patent/US20250017925A1/en active Pending
- 2024-09-06 JP JP2024154042A patent/JP2025003958A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2974902T3 (es) | Moduladores de los canales Kv3 para tratar el dolor | |
| EP3390394B1 (en) | Hydantoin modulators of kv3 channels | |
| ES2680246T3 (es) | Pirimidincarboxamidas como bloqueantes de canal de sodio | |
| JP7295169B2 (ja) | Ｂｔｋ阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法 | |
| CN102020651B (zh) | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 | |
| WO2013182851A1 (en) | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required | |
| HRP20050601A2 (en) | Chk-, pdk-, and akt-inhibitory pyrimidines, their production and use as pharmarmaceutical agents | |
| ES2784316T3 (es) | 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo | |
| US10934278B2 (en) | Compounds | |
| CN103271906A (zh) | 螺-吲哚酮化合物作为治疗剂的用途 | |
| CN104334548A (zh) | 作为kv3抑制剂的乙内酰脲衍生物 | |
| US20200039970A1 (en) | Hydantoin modulators of kv3 channels | |
| Czopek et al. | Synthesis and pharmacological evaluation of new 5-(cyclo) alkyl-5-phenyl-and 5-spiroimidazolidine-2, 4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity | |
| HK1262362A1 (en) | Modulators of kv3 channels to treat pain | |
| HK1262362B (en) | Modulators of kv3 channels to treat pain |